VYCOR MEDICAL INC 8-K

What Happened
Vycor Medical Inc. (VYCO) announced its financial results for the year ended December 31, 2025 by issuing a press release on March 31, 2026. The company furnished that press release as Exhibit 99.1 to an 8‑K (Item 2.02). The 8‑K states the press release and financial information are furnished (not "filed") and therefore are not subject to Section 18 liability or automatically incorporated by reference into other SEC filings.

Key Details

• Press release reporting full‑year 2025 results was issued and furnished on March 31, 2026 (Exhibit 99.1).
• Company presented non‑GAAP measures called "non‑GAAP Cash Operating Expenses" and "non‑GAAP Cash Operating Loss" that exclude Depreciation and non‑cash Stock Compensation.
• A reconciliation of these non‑GAAP measures to GAAP results is included in the press release.
• The 8‑K treatment: the results are furnished under Item 2.02 (Results of Operations and Financial Condition); the filing also references Item 9.01 for exhibits.

Why It Matters
This filing provides investors with Vycor’s latest year‑end financial results and management’s view of operating performance using adjusted (non‑GAAP) cash metrics that exclude depreciation and non‑cash stock compensation. Retail investors should review both the GAAP financial statements and the provided reconciliation to understand differences between reported GAAP results and the company’s non‑GAAP cash operating measures, which management uses to evaluate ongoing operations and trends.